Corporate insiders and 10% owners buy shares expecting a price increase, signaling potential growth for investors even during market uncertainties.
Notable insider purchases included a biotech IPO with insiders buying over 13.7 million shares, showing high confidence in Artiva Biotherapeutics' potential.
[
Collection
]
[
|
...
]